guest ::
| Home > Publications database > Network-based approach for drug repurposing against mpox. > print |
| 001 | 290332 | ||
| 005 | 20250820105511.0 | ||
| 024 | 7 | _ | |a 10.1016/j.ijbiomac.2024.132468 |2 doi |
| 024 | 7 | _ | |a pmid:38761900 |2 pmid |
| 024 | 7 | _ | |a 0141-8130 |2 ISSN |
| 024 | 7 | _ | |a 1879-0003 |2 ISSN |
| 024 | 7 | _ | |a altmetric:163519140 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2024-01060 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 570 |
| 100 | 1 | _ | |a Tang, Kang |b 0 |
| 245 | _ | _ | |a Network-based approach for drug repurposing against mpox. |
| 260 | _ | _ | |a New York, NY [u.a.] |c 2024 |b Elsevier |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1716358302_7220 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a The current outbreak of mpox presents a significant threat to the global community. However, the lack of mpox-specific drugs necessitates the identification of additional candidates for clinical trials. In this study, a network medicine framework was used to investigate poxviruses-human interactions to identify potential drugs effective against the mpox virus (MPXV). The results indicated that poxviruses preferentially target hubs on the human interactome, and that these virally-targeted proteins (VTPs) tend to aggregate together within specific modules. Comorbidity analysis revealed that mpox is closely related to immune system diseases. Based on predicted drug-target interactions, 268 drugs were identified using the network proximity approach, among which 23 drugs displaying the least side-effects and significant proximity to MPXV were selected as the final candidates. Lastly, specific drugs were explored based on VTPs, differentially expressed proteins, and intermediate nodes, corresponding to different categories. These findings provide novel insights that can contribute to a deeper understanding of the pathogenesis of MPXV and development of ready-to-use treatment strategies based on drug repurposing. |
| 536 | _ | _ | |a 315 - Bildgebung und Radioonkologie (POF4-315) |0 G:(DE-HGF)POF4-315 |c POF4-315 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 650 | _ | 7 | |a Comorbidity |2 Other |
| 650 | _ | 7 | |a Drug repurposing |2 Other |
| 650 | _ | 7 | |a Mpox |2 Other |
| 650 | _ | 7 | |a Virushost interaction |2 Other |
| 700 | 1 | _ | |a Sun, Qianru |b 1 |
| 700 | 1 | _ | |a Zeng, Jinfeng |b 2 |
| 700 | 1 | _ | |a Tang, Jing |b 3 |
| 700 | 1 | _ | |a Cheng, Peiwen |b 4 |
| 700 | 1 | _ | |a Qiu, Zekai |0 P:(DE-He78)58621186eeeae8ff31a0431a353c128f |b 5 |u dkfz |
| 700 | 1 | _ | |a Long, Haoyu |b 6 |
| 700 | 1 | _ | |a Chen, Yilin |b 7 |
| 700 | 1 | _ | |a Zhang, Chi |b 8 |
| 700 | 1 | _ | |a Wei, Jie |b 9 |
| 700 | 1 | _ | |a Qiu, Xiaoping |b 10 |
| 700 | 1 | _ | |a Jiang, Guozhi |b 11 |
| 700 | 1 | _ | |a Fang, Qianglin |b 12 |
| 700 | 1 | _ | |a Sun, Litao |b 13 |
| 700 | 1 | _ | |a Sun, Caijun |b 14 |
| 700 | 1 | _ | |a Du, Xiangjun |b 15 |
| 773 | _ | _ | |a 10.1016/j.ijbiomac.2024.132468 |g Vol. 270, no. Pt 2, p. 132468 - |0 PERI:(DE-600)1483284-7 |n Pt 2 |p 132468 |t International journal of biological macromolecules |v 270 |y 2024 |x 0141-8130 |
| 856 | 4 | _ | |u https://inrepo02.dkfz.de/record/290332/files/1-s2.0-S0141813024032732-main.pdf |
| 856 | 4 | _ | |u https://inrepo02.dkfz.de/record/290332/files/1-s2.0-S0141813024032732-main.pdf?subformat=pdfa |x pdfa |
| 909 | C | O | |o oai:inrepo02.dkfz.de:290332 |p VDB |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 5 |6 P:(DE-He78)58621186eeeae8ff31a0431a353c128f |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-315 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Bildgebung und Radioonkologie |x 0 |
| 914 | 1 | _ | |y 2024 |
| 915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |d 2023-10-21 |w ger |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b INT J BIOL MACROMOL : 2022 |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2023-10-21 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2023-10-21 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2023-10-21 |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b INT J BIOL MACROMOL : 2022 |d 2023-10-21 |
| 920 | 1 | _ | |0 I:(DE-He78)E055-20160331 |k E055 |l E055 KKE Molekulare Radioonkologie |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)E055-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|